Thursday, 8th December, 2005
A. An introduction to cachexia and anorexia
1. Cachexia in the centuries
Josef Fischer, Boston, MA, USA
2. Cachexia: prevalence and impact in medicine
Claude Pichard, Geneva, Switzerland
3. Anorexia: prevalence and impact in medicine
Michael Meguid, Syracuse, NY, USA
4. Health Care expenditure due to cachexia and cost of therapy
Wayne Levy, Seattle, WA, USA
5. Authority approved and guideline confirmed therapies of cachexia
Charles Loprinzi, Rochester, MN, USA |
B. What is cachexia and what is it not
Discussants:
Stefan Anker, Berlin, Germany
William Evans, Little Rock, AR, USA
John Morley, St. Louis, MI, USA
Annemie Schols, Maastricht, The Netherlands
6. Weight loss in ageing – sarcopenia is not cachexia ?!
David Thomas, St. Louis, MI, USA
7. Muscle wasting without weight loss: the case of rheumatoid arthritis
TBA
8. The most important feature of cachexia is inflammation
TBA
9. The hallmark of cachexia is weight loss
TBA
General discussion |
From 21.00
Faculty Dinner
Friday, 9th December, 2005
C. Common factors and mechanisms in cachexia
10. Pathophysiology of changes in energy intake in chronic illness
TBA
11. Pathophysiology of changes in energy expenditure in chronic illness
Steven Heymsfield, New York, NY, USA
12. Disuse atrophy vs. muscle wasting
Susan Kandarian, Boston, MA, USA
13. Lipolysis in chronic illness: pathophysiology and clinical implication
Peter Arner, Stockholm, Sweden
14. Hormones, cytokines and free radicals
Josep Argiles, Barcelona, Spain |
D. BASIC TRACK:
Mechanisms of muscle wasting
15. Muscular catabolic pathways
Vickie Baracos, Edmonton, Canada
16. Impaired muscle anabolism
Denis Guttridge, Columbus, OH, USA
17. Neural control of lean body mass
Antonio Musarò, Rome, ITA
18. Regulation of muscle mass by myostatin
Roger Hill, Groton, CT, USA |
E. CLINICAL TRACK:
Symptoms and comorbidities of patients with cachexia: pathophysiology and clinical impact
19. Muscle fatigue and weakness
Andrew Clark, Hull, UK
20. Shortness of breath
Andrew Coats, Sydney, Australia
21. Anorexia
Filippo Rossi Fanelli, Rome, Italy
22. Depression
Mauro Mauri, Pisa, Italy
23. The importance of anemia, hyperuricemia and insulin resistance
Wolfram Doehner, Berlin, Germany |
F. BASIC TRACK:
Pathophysiology of tissue wasting
24. Ubistatins
Raymond Deshaies, Pasadena, CA, USA
25. Hormone resistance syndromes
Christian J. Strasburger, Berlin, Germany
26. Leptin, Ghrelin, PYY and beyond
Matthias Tschöp, Cincinnati, OH, USA
27. Innate immunity in cachexia
Ralf Schumann, Berlin, Germany
28. Males/females: does it make a difference?
Nori Geary, Zurich, Switzerland |
G. CLINICAL TRACK:
The clinical approach
29. Cachexia in COPD
Annemie Schols, Maastricht, The Netherlands
30. Cachexia in chronic heart failure
Piotr Ponikowski, Wroclaw, Poland
31. Cachexia in renal failures
William Mitch, Galveston, TX, USA
32. Cachexia in chronc liver failure
TBA
33. Lessons on cachexia in CHF and COPD from large-scale trials
TBA |
H. Therapeutic options in cachexia – the present
34. Key note lecture: Growth hormone
Ezio Ghigo, Turin, Italy
35. Appetite stimulants
William Evans, Little Rock, AR, USA
36. AIDS-related cachexia
TBA
37. Intensive nutritional counselling
Paula Ravasco, Lisbon, Portugal
38. Anabolic steroids
Kathleen Mulligan, San Francisco, CA, USA |
From 19.30
Anti-cachexia Dinner
Dinner Talk: Baroque in Rome
Kenneth Fearon, Edinburgh, UK
Saturday, 10th December, 2005
I. Therapeutic options in cachexia – current studies and concepts
39. EPA in cachexia
Attilio Giacosa, Genova, Italy
40. IGF-I et al.
Ross Clark, Auckland, New Zealand
41. Gene therapy trials
Jeffrey Chamberlain, Seattle, WA, USA
DEBATE: Should the focus be on gaining muscle tissue?
42. PRO: Only muscle tissue counts!
Maurizio Muscaritoli, Rome, Italy
43. CONTRA: Increasing fat mass is at least as important!
John Morley, St. Louis, MI, USA |
K. BASIC TRACK:
Cell death and recovery – therapeutic implications
44. Targeting muscular catabolic pathways
Paola Costelli, Turin, Italy
45. The role of apoptosis in catabolism
Marco Sandri, Padua, Italy
46. Ubiquitination vs. ubiquitin-independent proteolysis
Didier Attaix, Clermont-Ferrand, France
47. The role of cytokines
Lyle Moldawer, Gainesville, FL, USA |
L. CLINICAL TRACK:
Cancer cachexia
48. Pathophysiology of cancer cachexia – much more than host-tumor-interaction
Kenneth Fearon, Edinburgh, UK
49. Approved therapies for cancer cachexia: a critical review
Maurizio Bossola, Rome, Italy
50. Integrated artificial nutrition
Kent Lundholm, Göteborg, Sweden
51. Update on clinical trials in cancer cachexia
Florian Strasser, Zurich, Switzerland |
M. BASIC TRACK:
Treatment approaches closer to reality
52. Targeting cytokines – why and how?
Hans-Dieter Volk, Berlin, Germany
53. Targeting the ubiquitination pathway
David Glass, Tarrytown, NY, USA
54. Ghrelin and ghrelin analogues
Michael D. Culler, Paris, France
55. Myostatin antibodies
TBA |
N. CLINICAL TRACK:
Anorexia and appetite stimulation
56. Pathophysiology of appetite regulation
TBA
57. Branched-chain amino acids
Alessandro Laviano, Rome, Italy
58. Role of orexigenic peptides in the treatment of cancer anorexia Akio Inui, Kobe, Japan
59. Megestrol acetate – an overview of its application
Aminah Jatoi, Rochester, MN, USA |
O. Cachexia research 2005 – where to go ?
60. Key note lecture: From molecular biology to new therapeutic targets
TBA
61. News from published patents
Stefan Anker, Berlin, Germany
62. Helping the skeletal musculature – stem cell therapy
Nadia Rosenthal, Rome, Italy
63. Rebuilding tissues – triggering myocyte rejuvenation
Rüdiger von Harsdorf, Berlin, Germany |
Closing Remarks
 |
